

SYNTHESIS OF OPTICALLY ACTIVE (PIVALOYLOXY)METHYL 2',3'-SUBSTITUTED
4'-OXOAZETIDIN-1'-YL-3-METHYLBUT-2-ENOATES FROM 6-APA


CARMEN SOMOZA AND ORESTE A. MASCARETTI*

Instituto de Química Orgánica de Síntesis (CONICET-UNR)
Facultad de Ciencias Bioquímicas y Farmacéuticas,
Casilla de Correo 991, 2000 Rosario, Argentina

(Received in USA 21 March 1988)

Abstract - The title compound were prepared as useful optically active intermediates for the synthesis of "non-classical" β -lactam compounds. These monocyclic azetidiones were formed by cleavage of sulfur-carbon 5 bond of bicyclic penicillanates with chlorine or tert-butyl hypochlorite in appropriate solvents.

Since the discovery of nocardicins **1**¹, the first biologically active monocyclic β -lactams, which was followed by the monobactams **2**^{1c,2}, the therapeutic potential of derivatives of 4-azetidiones has been widely recognized.^{1b,c,2b} Another class of natural products, the clavulanic acid **3**^{3a}, the carbapenems **4**^{3b}, the 1-oxacephalosporins **5**^{3c} and other "non-classicals" bicyclic β -lactams, has dramatically increased the research directed to the synthesis of functionalized 4-azetidiones as key intermediates of several synthetic approaches to these β -lactam derivatives.^{4,5} Among those intermediates (3'-substituted-2'-chloro-4'-oxoazetid-1'-yl)-3-methylbut-2-enoate ester derivatives **6** were used as one of the key features of different strategies leading to the preparation of various β -lactam derivatives.⁶ N-aryl- 3-halogeno- and 3,3-dihalogeno-4-azetidiones have recently been synthesized and their β -lactamase inhibitory activity evaluated.⁷




We were particularly interested in developing a practical route for the synthesis of optically active (pivaloyloxy)methyl (Pom) 2-[2'-Chloro-3'-Bromo-2'-oxoazetidin-1'-yl]-3-methylbut-2-enoate **9,11** starting from 6-aminopenicillanic acid (6-APA) **7**, which is abundantly available and inexpensive.

A number of methods exist to cleave 1-5 bond of penam nucleus⁸ to arrive at monocyclic 4-azetidinones of general structures **6**. These products are typically formed when a non-6-acylamino side chain penicillanate ester is treated with an electrophilic reagent as chlorine,⁹ sulfonyl chloride⁹ and 1-chlorobenzotriazole¹⁰ in suitable solvents such as carbon tetrachloride, chloroform or methylene chloride, followed by treatment with a tertiary base, which gives rise to the removal of the 3-H atom as proton.


RESULTS AND DISCUSSION

In this paper we report a quite fruitful investigation on a practical method involving cleavage of 1-5 bond of Pom penicillanate being a synthetically useful method for the semi-synthesis of the optically active 4-azetidinones **9, 11** and **18**. Electrophilic opening reaction with chlorine.

Treatment of Pom 6 α -bromopenicillanate **8a** with 2.5 equiv. of chlorine in CCl₄-CHCl₃ at -70°C and immediate decomposition of polar intermediates by silica gel gives a mixture of the two isomeric compounds, **9** and **10** in a ratio 10:1 in 63% yield. Eq. (1). A comparable result was obtained when the base N-methyl piperazine was used to decompose the intermediate products. The pure isomers, were isolated by preparative TLC over silica gel.




When **8b** was treated under similar conditions as mentioned above, a mixture of **11** and **12** was produced in a ratio of 18:1 in 79% yield. Eq. (2).



The pairs of compounds **9-11** and **10-12** are enantiomers. Structure proof for compounds **9-12** was provided by ¹H and ¹³C NMR, mass spectra and IR spectroscopy. The ¹H NMR spectra show the H(5)-H(6) coupling constants of ca. 1.0 and 4.0 Hz to be consistent with the presence of a trans and cis-substituted β -lactam respectively.¹¹

When the chlorination of **8a** was run in an NMR tube and followed by ¹H NMR spectroscopy, clean conversion of starting material into the penicillanate chlorosulfonium chloride salt **13a** or its sulfurane form **13b** was revealed.^{12,13} Howev-

er it was not possible to distinguish between these forms (scheme I).



Scheme I


To explain the stereoselectivity of these reactions, we have to take into account the following features: i) the carbon 5 of penicillins is an aminothioketal; ii) the sulfur atom in the penicillanate chlorosulfonium chloride salt or in its sulfurane form is a very good leaving group, and iii) the unshared electron pair of the nitrogen atom can assist the heterolytic cleavage of sulfur-carbon 5 bond with concomitant departure of sulfonium or sulfurane group, leading to the azetidinium cation **14** which, as it is known,⁹ is attacked by a nucleophile, preferentially from the opposite orientation (α or β) of the bulkier substituent on carbon 6. The olefin forming reaction which may be synchronic with or subsequent to the rupture of 1-5 bond, has been explained⁹ by the β -elimination of the hydrogen on carbon 3, abstraction as a proton by the chloride anion or by added base with liberation of sulfur dichloride (SCl_2).

Denerly and Thomas¹³ have reported that the decomposition of penicillanate methyl-sulfonium tetrafluoroborate or fluorosulfonate with anhydrous sodium carbonate led to olefin formation by loss of H(3) as proton and cleavage of sulfur-carbon 2 bond. A similar bond cleavage has been reported in the Nayler reaction.¹⁴

Electrophilic opening reaction with tert-butyl hypochlorite.

Tert-butyl hypochlorite $(\text{CH}_3)_3\text{CCOCl}$ has been utilized extensively in radical¹⁶ and ionic¹⁷ reactions with thioethers and benzyl penicillanate methyl ester.¹⁸ We report here on the reaction of tert-butyl hypochlorite with Pom 6 α - and 6 β -bromo-penicillanates **8a,b** and Pom 6,6-dibromopenicillanate **15**, under a variety of conditions (See experimental section).

We found that reaction of $(\text{CH}_3)_3\text{CCOCl}$ with **15** in the presence of azo-bis (isobutyronitrile) (AIBN) as radical initiator at 30°C followed by decomposition of unstable intermediates with silica gel yields Pom 2-(2'-chloro-3',3'-dibromo-4'-oxoazetidin-1'-yl) and Pom 2-(2'-tert-butoxy-3',3'-dibromo-4'-oxoazetidin-1'-yl)-3-methylbut-2-enoates **16** and **17** in a ratio 19:1, 45% yield. See eq. (3). When



79.5 $-\text{CH}_2-$, 117.1 C-2, 158.9, 159.5 and 160.6 (C-1,3,4'), 176.6 $-\text{OC}(\text{O})\text{C}(\text{CH}_3)_3$; MS (70 ev) m/e 395 (M^+), 365 (M^+-30), 85 and 57.

Pom 2-[(2'S,3'S)-2'-chloro-3'-bromo-4'-oxoazetididin-1'-yl]-3-methylbut-2-enoate (10) was isolated as 3.3 mg (6.5%) of a clear oil: IR 1815 (C=O, β -lactam), 1760 cm^{-1} (C=O, ester); ^1H NMR δ 1.22 (9 H, s, $-\text{C}(\text{CH}_3)_3$), 2.05 and 2.32 (each 3 H, s, $-\text{C}(\text{CH}_3)_2$), 5.50 (1 H, d, 3'-H, J=4.0 Hz), 5.77 and 5.88 (each 1 H, d, $-\text{CH}_2-$, J=5.6 Hz), 6.05 (1 H, d, 2'-H, J=4.0 Hz).

Reaction of Pom 6 β -bromopenicillanate (8b) with chlorine. A solution of (8b) (35.7 mg, 0.091 mmol) in dry chloroform, was cooled at -70°C and stirred during the addition of a solution of chlorine in carbon tetrachloride (0.5 M, 1 ml). The mixture was warm at room temperature and N-methyl piperazine (0.05 ml) was added and the mixture was stirred for an additional 15 min, and concentrated. The resultant oil (28.4 mg) was filtered through silica gel 60 H (2 g) using chloroform as eluant yielding a mixture of Pom 2-[(2'S,3'R)-2'-chloro-3'-bromo-4'-oxoazetididin-1'-yl]-3-methylbut-2-enoate (11) 26.9 mg (75%) and Pom 2-[(2'R,3'R)-2'-chloro-3'-bromo-4'-oxoazetididin-1'-yl]-methylbut-2-enoate (12) 1.5 mg (4%).

For the ^1H NMR assignment of compounds 11 and 12, see above the reported values for the enantiomers 9 and 10 respectively.

Intermediates 13a or 13b. To a solution of 8a (9 mg) in CDCl_3 (0.3 ml) in an NMR tube, was added a solution of chlorine in CCl_4 (1.0 M, 0.2 ml). After 15 min. the ^1H NMR spectrum was recorded, showing that all the signals of starting material (8a) disappear. ^1H NMR of 8a δ 1.22 (9 H, s, 12-H), 1.50 and 1.62 (each 3 H, s, 13 and 14-Me), 4.57 (1 H, s, 3-H), 4.81 (1 H, d, 5-H, J=2.0 Hz), 5.41 (1 H, d, 6-H, J=2.0 Hz), 5.81 and 5.84 (each 1 H, d, 9-H, J=5.6 Hz). Intermediates 13a or 13b δ 1.22 (9 H, s, $-\text{C}(\text{CH}_3)_3$), 1.54 and 1.71 (each 3 H, s, 13 and 14-Me), 4.41 (1 H, s, 3-H), 4.77 (1 H, d, 5-H, J=2.0 Hz), 5.37 (1 H, d, 6-H, J=2.0 Hz), 5.80 and 5.82 (each 2 H, br. s. $-\text{CH}_2-$). To decompose these intermediates 0.005 ml of pyridine was added, and after 20 min. the ^1H NMR spectrum was recorded, showing the typical signals of compounds 9 and 10.

Reaction of Pom 6,6-dibromopenicillanate (15) with tert-butyl hypochlorite. A solution of 15 (130 mg, 0.275 mmol), in dichloromethane (5 ml) was stirred at 30°C during the addition of tert-butyl hypochlorite (4.0 mmol) and AIBN (4 mg, 0.02 mmol). After the addition was completed, the solution was stirred at room temperature (30°C), concentrated and the residue was purified by preparative TLC on silica gel using 95:5 benzene-chloroform as eluant yielding 56 mg (43%) of Pom 2-[(2'-chloro-3',3'-dibromo-4'-oxoazetididin-1'-yl)-3-methylbut-2-enoate (16) as a clear oil, R_f 0.48 in benzene, $[\alpha]_D^{20} = -9.4$ ($c=1.90$, CHCl_3); IR 1820 (C=O, β -lactam), 1760 cm^{-1} (C=O, ester); ^1H NMR δ 1.22 (9 H, s, $-\text{C}(\text{CH}_3)_3$), 2.03 and 2.35 (each 3 H, s, $-\text{C}(\text{CH}_3)_2$), 5.79 and 5.91 (each 1 H, d, $-\text{CH}_2-$, J=5.6 Hz), 6.18 (1 H, s, 2'-H); ^{13}C NMR δ 22.3 and 23.8 $-\text{C}(\text{CH}_3)_2$, 26.7 $-\text{C}(\text{CH}_3)_3$, 56.3 C-3', 79.6 ($-\text{CH}_2-$), 81.0 C-2', 115.9 C-2, 160.6 and 161.7 (C-1,3,4'), 177.0 $-\text{OC}(\text{O})\text{C}(\text{CH}_3)_3$; MS (70 ev) m/e 473 (M^+22), 443 (M^+-30), 85 and 57.

Pom 2[(2'-tert-butoxy-3',3'-dibromo-4'-oxoazetididin-1'-yl)-3-methylbut-2-enoate (17). 3.9 mg (2.3%) $[\alpha]_D^{20} = +2.64$ ($c=0.75$, CHCl_3); IR 1800 (C=O, β -lactam), 1760 cm^{-1} (C=O, ester); ^1H NMR δ 1.22 (9 H, s, $-\text{C}(\text{CH}_3)_3$), 1.29 (9 H, s, $-\text{O}-\text{C}(\text{CH}_3)_3$), 2.02 and 2.30 (each 3 H, s, $-\text{C}(\text{CH}_3)_2$), 5.5 (1 H, s, 2'-H), 5.75 and 5.90 (each 1 H, d, $-\text{CH}_2-$, J=5.6 Hz); ^{13}C NMR δ 22.2 and 23.8 $-\text{C}(\text{CH}_3)_2$, 27.0 $-\text{C}(\text{CH}_3)_3$, 28.4 $-\text{O}-\text{C}(\text{CH}_3)_3$, 38.8 $-\text{O}-\text{C}(\text{O})\text{C}(\text{CH}_3)_3$, 60.3 $-\text{O}-\text{C}(\text{CH}_3)_3$, 65.8 C-3', 80.3 ($-\text{CH}_2-$), 89.4 C-2', 107.3 C-2, 159.4, 160.7 and 161.6 (C-1,3,4'); MS (FIB) 512 (MH^+22), MS (chemical ionization), 510 (M^+-H)²², 455 ($\text{MH}^+-\text{C}_4\text{H}_8$), 346 ($\text{M}^+-\text{C}_5\text{H}_8\text{BrO}$), 85 and 57.

Reaction of Pom 6 α -bromopenicillanate (8a) with tert-butyl hypochlorite.

Method A. To a solution of 8a (100 mg, 0.25 mmol) in dry chloroform (10 ml) was added 0.5 g of silica gel 60 H and the mixture was stirred at 30°C during the addition of tert-butyl hypochlorite (0.90 mmol). After the addition was completed, the mixture was stirred 15 min at room temperature, filtered and concentrated yielding 80.5 mg (80%) of compound 9.

Method B. A solution of 8a (100 mg, 0.25 mmol) in dry chloroform (10 ml) and 0.2 ml of tert-butanol was stirred at room temperature during the addition of tert-butyl hypochlorite (0.90 mmol). After stirring for 15 min, N-methyl piperazine (0.1 ml) was added and the mixture was stirred for an additional 30 min and concentrated. The resultant oil was dissolved in chloroform and filtered through silica gel 60 H (2.5 g) using chloroform as eluant yielding 90 mg (93%) of compound 9.

Reaction of Pom 6 β -bromopenicillanate (8b) with tert-butyl hypochlorite. A solution of (8b) (25.1 mg, 0.064 mmol) in dry chloroform (2 ml) was stirred at 30°C during the addition of tert-butyl hypochlorite (0.27 mmol). After stirring for 5 min, N-methyl piperazine (0.02 ml) was added and the mixture was stirred for an additional 30 min and concentrated. The resultant oil (26 mg) was dissolved in chloroform filtered through silica gel (2 g) using chloroform as eluant yielding 22.0 mg (85%) of a mixture of 11 and 12 in a ratio of 5:1, determined by ^1H NMR spectroscopy.

Reaction of Pom 6 α -bromopenicillanate 8a with distilled tert-butyl hypochlorite. A solution of 8a (45 mg, 0.114 mmol) in dry chloroform (2 ml) was stirred at room temperature during the addition of distilled tert-butyl hypochlorite (0.365 mmol). After stirring for 5 min, N-methyl piperazine (0.05 ml, 0.45 mmol) was added and the solution was stirred for an additional 5 min and concentrated. The crude product was filtered through silica gel using chloroform as eluant yielding 42 mg (85%) of Pom 2-[(2'S,3'R)-2'-tert-butoxy-3'-bromo-4'-oxoazetididin-1'-yl]-3-methylbut-2-enoate (18), as an oil: IR 1790 (C=O, β -lactam), 1760 cm^{-1} (C=O, ester); ^1H NMR δ 1.23 (18 H, s, $-\text{O}-\text{C}(\text{O})\text{C}(\text{CH}_3)_3$ and $-\text{O}-\text{C}(\text{CH}_3)_3$), 2.03 and 2.29 (each 3 H, s, $-\text{C}(\text{CH}_3)_2$), 4.46 (1 H, d, 3'-H, J=1.0 Hz), 5.39 (1 H, d, 2'-H, J=1.0 Hz), 5.74 and 5.90 (each 1 H, d, $-\text{CH}_2-$, J=5.6 Hz); ^{13}C NMR δ 21.8 and 23.8 $-\text{C}(\text{CH}_3)_3$, 26.7 $-\text{O}-\text{C}(\text{O})\text{C}(\text{CH}_3)_3$, 28.1 $-\text{O}-\text{C}(\text{CH}_3)_3$, 38.6 $-\text{O}-\text{C}(\text{O})\text{C}(\text{CH}_3)_3$, 49.6 (C-3'), 75.5 $-\text{O}-\text{C}(\text{CH}_3)_3$, 80.2 ($-\text{CH}_2-$), 86.7 (C-2'), 117.5 (C-2), 158.7, 161.4 and 161.6 (C-1,3,4'), 176.9 $-\text{O}-\text{C}(\text{O})\text{C}(\text{CH}_3)_3$; MS (FIB) 434 (MH^+22), 378 ($\text{MH}^+-\text{C}_4\text{H}_8$), 246, MS (chemical ionization) 433 (M^+22), 377 ($\text{M}^+-\text{C}_4\text{H}_8$), 245, 103 and 85.

Acknowledgments. The authors thank CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas) for financial support and fellowship (C.S.). We also thank Prof. M.G. Sierra (IQUIOS) for helpful discussions and Prof. H. Duddeck (Ruhr-Universität Bochum) for the FIB mass spectral data.

REFERENCES AND NOTES

1. a) Aoki, H.; Sakai, H.; Kohsaka, M.; Konomi, T.; Hoesoda, J.; Kubochi, T.; Iguchi, E.; Imanaka, H. *J. Antibiot.* 1976, **29**, 492. For a review see: b) Kamiya, T.; Aoki, H.; Mine, Y. In "Chemistry and Biology of β -Lactam Antibiotics" Morin, R.B.; Gosman, M. Eds.; Academic Press, New York, 1982, Vol. 2; p. 165-226, c) Durckheimer, W.; Blumbach, J.; Lattrell, R.; Scheunemann, K.H. *Angew. Chem. Int. Ed. Engl.* 1985, **24**, 180.
2. a) Sykes, R.B.; Cimarusti, C.M.; Borner, D.F.; Bush, K.; Floy, D.M.; Georgopadakou, N.H.; Koster, W.H.; Liu, W.C.; Parker, W.L.; Principe, P.A.; Rathnum, M.L.; Slusarchyk, W.A.; Trejo, W.H.; Wells, J.S. *Nature (London)*, 1981, **291**, 489, b) For a review see: Cimarusti, C.M.; Sykes, R.B. *Med. Res. Rev.*, 1984, **4**, 1.
3. a) Cherry, P.C.; Newall, C.E. *ibid ref. 1b*, p. 361-402, b) Ratcliffe, R.W.; Albers-Schonberg, G. *ibid ref. 1b*, p. 227-313, c) Nagata, W.; Narisada, M.; Yoshida, T. *ibid ref. 1b*, p. 1-97.
4. a) For a review see: Miller, M.J. *Acc. Chem. Res.* 1986, **19**, 49, b) Rajendra, G.; Miller, M.J. *J. Org. Chem.* 1987, **52**, 4471, c) Kolasa, T.; Miller, M.J. *Tetrahedron Lett.* 1987, **28**, 1861, d) Cossio, F.P.; Gamboa, J.; Garcia, J.M.; Leosa, B.; Palomo, C. *Tetrahedron Lett.* 1987, **28**, 1945 and references therein.
5. For recent leading references see: a) Chackalamannil, S.; Fett, N.; Kirkup, M.; Afonso, A.; Ganguly, A.K. *J. Org. Chem.* 1988, **53**, 450, b) Manhas, M.S.; Magle, D.R.; Chiang, J.; Bose, A.K. *Heterocycles*, 1988 **27**, 1755, c) Maruyama, H.; Hiraoka, T. *J. Org. Chem.* 1986, **51**, 399, d) Wei, C.C.; DeBernardo, S.; Teng, J.P.; Borgese, J.; Weigle, M. *J. Org. Chem.* 1985, **50**, 3462, e) Barret, A.G.M.; Graboski, G.G.; Russell, M.A. *J. Org. Chem.* 1985, **50**, 2603, f) Wasserman, H.H.; Han, W.T.; *J. Am. Chem. Soc.* 1985, **107**, 1444, g) Martel, A.; Daris, J.P.; Bachard, C.; Menard, M.; Durst, C.; Belleau, B. *Can. J. Chem.* 1983, **61**, 1899, h) Hirai, K.; Iwano, Y.; Fujimoto, K. *Heterocycles*, 1982, **17**, 201, i) Pfeil, J.L.; Kukolja, S.; Paquette, L.A. *J. Org. Chem.* 1981, **46**, 829, j) Cimarusti, C.M.; Applegate, H.E.; Chang, H.W.; Floyd, D.M.; Koster, W.H.; Slusarchyk, W.A.; Young, M.G. *J. Org. Chem.* 1982, **47**, 179.
6. For the use of 2-[2'-chloro-3'-substituted-4'-oxoazetidino-1'-yl]-3-methylbut-2-enoate ester derivatives as intermediates in the synthesis of β -lactam compounds, see: Wolfe, S.; Shaw, C.C. *Can. J. Chem.* 1982, **60**, 144, b) Beels, C.M.D.; Abu-Rabie, S. *J. Chem. Soc., Chem. Commun.* 1979, 665, c) Giriavalabhan, V.M.; Ganguly, A.K.; McCombie, S.W.; Pinto, P.; Rizvi, R. *Tetrahedron Lett.* 1981, **22**, 3485, d) Aratani, M.; Hagiwara, D.; Takeno, H.; Hemmi, K.; Hashimoto, M. *J. Org. Chem.* 1980, **45**, 3682, e) Micotich, R.G.; Singh, R.; Merlo, W.O.; Tetteh, D.M.; Shaw, C.C.; Morin, R.B. *Heterocycles*, 1984, **22**, 2757, f) Onoue, H.; Narisada, M.; Uyeo, S.; Matsumura, H.; Okada, K.; Yano, T.; Nagata, W. *Tetrahedron Lett.* 1979, **40**, 3867, g) Tonge, A.P.; Ward, P. *Synth. Commun.* 1982, **12**, 117.
7. Joyeau, R.; Molines, H.; Labia, R.; Wakselman, M. *J. Med. Chem.* 1988, **31**, 370.
8. For a review, see: Stoodley, R.J. *Tetrahedron*, 1975, **31**, 2321.
9. Kukolja, S. *J. Am. Chem. Soc.* 1971, **93**, 6267.
10. Kukolja, S.; Lammert, S.R. *Croat. Chim. Acta*, 1972, **44**, 423.
11. Barrow, K.D.; Spotswood, T.M. *Tetrahedron Lett.* 1965, 3325, b) Green, G.H.F.; Page, J.E.; Stanforth, S.E. *J. Chem. Soc. C*, 1965, 1595, c) Demaroo, P.V.; Nagarajan, R. In "Cephalosporin and Penicillins" Ed. Flynn, E.H., Academic Press, New York, 1972, p. 330.
12. For a recent review of the structure and reactivity of halogenosulfonium salts, see: Wilson, G.E., *Tetrahedron*, 1982, **38**, 2597.
13. Denerly, M.; Thomas, E.J. *J. Chem. Soc., Perkin Trans. 1*, 1979, 3185, have isolated and characterized 1 α -S-methylsulfonium salts of methyl 6 α -chloro- and 6,6-dibromopenicillanates, having the non-basic, super weak nucleophiles BF_4^- and FSO_3^- as counterions.
14. a) Clayton, J.P.; Nayler, J.H.C.; Southgate, R.; Tolliday, P. *J. Chem. Soc., Chem. Commun.* 1971, 590, b) Clayton, J.P.; Nayler, J.H.C.; Pearson, M.J.; Southgate, R. *J. Chem. Soc., Perkin Trans. 1*, 1974, **22**, c) Brain, E.G.; McMillan, I.; Nayler, J.H.C.; Southgate, R.; Tolliday, P. *J. Chem. Soc. Perkin Trans. 1*, 1974, 562.
15. Mintz, M.J.; Walling, C. *Organic Syntheses*, J. Wiley & Sons, New York, 1973, *Collect Vol. 4*, p. 184.
16. a) Walling, C.; Jackow, B.B. *J. Am. Chem. Soc.*, 1960, **82**, 6108 and 6113, b) Gritter, R.J.; Carey, D.J. *J. Org. Chem.* 1964, **29**, 1160.
17. a) Johnson, C.R.; Rigau, J.J. *J. Am. Chem. Soc.*, 1969, **91**, 5398, b) Skattebol, L.; Boulette, B.; Solomon, S. *J. Org. Chem.*, 1967, **32**, 3111, c) Walling, C.; Mintz, M.J. *J. Org. Chem.* 1967, **32**, 1286.
18. The cleavage of sulfur-carbon 5 in benzylpenicillanate methyl ester was reported albeit without experimental detail. See: Sheehan, J.C. "Molecular Modification in Drug Design", *Advances in Chemistry Series N 45*, American Chemical Society, Washington, D.C. 1964, p. 15.
19. a) Swern, D.; Clements, A.H.; Luong, T.M. *Analyt. Chem.*, 1969, **41**, 412, b) Ward, G.A.; Mair, R.D. *Analyt. Chem.*, 1969, **41**, 538.
20. Bellinzoni, D.U.; Setti, E.L.; Mascaretti, O.A. *J. Chem. Research*, 1988 (S), 176, (M), 1501.
21. Setti, E.L.; Mascaretti, O.A. *J. Org. Chem.*, 1986, **51**, 3217.
22. Several compounds characterized had one chlorine and/or one or two bromine atoms per molecule. For these compounds, characteristic isotope peaks were observed in their mass spectra; only the isotope lowest mass peaks are reported here.